PCI boosts Ireland investment pre-Brexit with new clinical facility

By Melissa Fassbender contact

- Last updated on GMT

(Image: PCI Pharma Services)
(Image: PCI Pharma Services)

Related tags: Pci pharma services, Brexit, Ireland

As part of its global network expansion strategy, PCI Pharma Services is investing in a new dedicated clinical facility near Dublin, Ireland, which will provide space for secondary packaging, storage, logistics, and distribution.

Once completed, the building will span more than 75,000 square feet, including additional controlled room temperature and cold chain storage capabilities as well as clinical packaging services.

Work is set to take place over the coming months and complements PCI’s​ current footprint in Dublin, which was established after its acquisition of Millmount Healthcare in 2017.

Licensed by the Health Products Regulatory Authority (HPRA), the facility offers clinical storage and distribution (S&D) for the shipment of investigational medicinal products (IMP) within the EU and globally.

Other services include cold chain handling, packaging, and storage for clinical and commercial products as well as serialization services and analytical release testing. 

Salim Haffar, CEO of PCI said in a statement: “Our growth strategy is focused on the continued expansion of our global network to support growing demand from our customers and providing a solution for Brexit through ongoing investment in capacity, capability expansion and talent.”

Haffar told us the company selected this location because it is close to its existing facility, in addition to the amount of local talent. The Dublin location is also its center of excellence for European operations.

"PCI Pharma Services is growing globally across all three of our sectors – development and manufacturing, clinical supplies and logistics, and commercial drug packaging technology,"​ he added. "More specifically, our fastest growth area is our clinical supplies and logistics business, which has been expanding across Europe and where Dublin is a key site for our operations."

Related news

Show more

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars